Cilnivas5 mg

Cilnivas 5 mg is indicated for the management of hypertension for end-organ protection. It is reported to be useful in elderly patients and in those with diabetes and albuminuria. Cilnivas 5 mg has been increasingly used in patients with chronic kidney diseaseHypertension is the term used to ... Read moreCilnivas 5 mg is indicated for the management of hypertension for end-organ protection. It is reported to be useful in elderly patients and in those with diabetes and albuminuria. Cilnivas 5 mg has been increasingly used in patients with chronic kidney diseaseHypertension is the term used to describe the presence of high blood pressure. The blood pressure is generated by the force of the blood pumped from the heart against the blood vessels. Thus hypertension is caused when there is too much pressure on the blood vessels and this effect can damage the blood vessel

Calcium-channel blockers

Cilnivas 5 mg is a dihydropyridine calcium-channel blocker. Cilnivas 5 mg binds to the dihydropy-ridine binding sites of the L-type voltage dependent calcium channel and inhibits Ca2+ influx across the cell membranes of vascular smooth muscle cells via this channel, consequently vascular smooth muscle is relaxed, causing vasodilation. Cilnivas 5 mg inhibits Ca2+ influx via N-type voltage dependent calcium channels in the sympathetic nerve cell membrane. The inhibition of Ca2+ influx via N-type voltage dependent calcium channel was observed over a similar range of drug concentrations to those inhibiting L-type voltage dependent Ca2+ channels. Consequently, release of norepinephrine from sympathetic nerve terminals would be inhibited. Cilnivas 5 mg is considered to suppress the reflex increase in heart rate after blood pressure reduction.

Adults: 5-10 mg once daily after breakfast. Maximum dose: 20 mg once daily. The safety of Cilnivas 5 mg in pediatric patients has not been established.Use in the elderly: Since the elderly may be more susceptible to hypotension, therapy should be initiated with the lowest possible dose (5 mg).

Adults: 5-10 mg once daily after breakfast. Maximum dose: 20 mg once daily. Pediatric use: The safety of Cilnivas 5 mg in pediatric patients has not been established.Elderly use: Since the elderly may be more susceptible to hypotension, therapy should be initiated with the lowest possible dose (5 mg).

Other anti-hypertensive, antipsychotics that cause hypotension, quinidine, carbamazepine, phenytoin, rifampicin, cimetidine, erythromycin.

Cilnivas 5 mg is contraindicated in patients with known sensitivity to Cilnivas 5 mg or any of the excipients or patients having cardiogenic shock, recent MI or acute unstable angina and severe aortic stenosis.

The most common side effects of Cilnivas 5 mg are: Dizziness; flushing; headache; hypotension; peripheral oedema; palpitations; GI disturbances; increased micturition frequency; lethargy; eye pain; depression.

Cilnivas 5 mg should not be administered in pregnant woman or woman having possibilities of being pregnant. It is also advisable to avoid the administration of Cilnivas 5 mg to nursing mothers. However, if the administration is indispensable, the patient should be instructed to discontinue lactation.

Cilnivas 5 mg should be administered with care in the following patients: patients with serious hepatic dysfunction, patients with a history of serious adverse reactions to calcium antagonists. During the discontinuation, the dosage should be gradually decreased under close observation.

Store below 30°C, protected from light and moisture. Keep away from reach out of the children.

Calcium-channel blockers

Cilnivas 5 mg is a dihydropyridine calcium-channel blocker. Cilnivas 5 mg binds to the dihydropy-ridine binding sites of the L-type voltage dependent calcium channel and inhibits Ca2+ influx across the cell membranes of vascular smooth muscle cells via this channel, consequently vascular smooth muscle is relaxed, causing vasodilation. Cilnivas 5 mg inhibits Ca2+ influx via N-type voltage dependent calcium channels in the sympathetic nerve cell membrane. The inhibition of Ca2+ influx via N-type voltage dependent calcium channel was observed over a similar range of drug concentrations to those inhibiting L-type voltage dependent Ca2+ channels. Consequently, release of norepinephrine from sympathetic nerve terminals would be inhibited. Cilnivas 5 mg is considered to suppress the reflex increase in heart rate after blood pressure reduction.

Cilnivas 5 mg should not be administered in pregnant woman or woman having possibilities of being pregnant. It is also advisable to avoid the administration of Cilnivas 5 mg to nursing mothers. However, if the administration is indispensable, the patient should be instructed to discontinue lactation.